Marfella 2006

Methods	A randomised, placebo‐controlled trial
Participants	40 people who presented with symptoms of cerebral ischaemic attack were included and randomised as 1:1 into the trial.
Interventions	Rosiglitazone 8 mg per day or placebo was given for 4 months.
Outcomes	Ubiquitin‐proteasome activity
Notes	We did not include 38 people with asymptomatic carotid stenosis in this review.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of random sequence generation was not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment was not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to judge
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The specimens were analysed by an expert pathologist blinded to the participant's diagnosis.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No participant in either group discontinued the treatment.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes were reported.
Other bias	Unclear risk	Information about financial support was not provided.